FibroBiologics Approves 1-for-20 Reverse Split to Regain Nasdaq Compliance
FibroBiologics will implement a 1-for-20 reverse stock split effective March 30, 2026, reducing its outstanding shares from 70,256,883 to approximately 3,512,845 to meet Nasdaq’s minimum bid price listing requirement. The split will proportionately adjust equity awards and options, with fractional shares rounded up to the nearest whole share.
1. Approval and Effective Date
The Board of Directors approved a 1-for-20 reverse stock split following stockholder authorization on February 20, 2026. The split will become effective at 12:01 a.m. Eastern Time on March 30, 2026, with split-adjusted trading to commence on Nasdaq that day.
2. Reverse Split Mechanics
Under the split, every twenty shares of common stock will combine into one share, reducing the issued and outstanding shares from 70,256,883 to approximately 3,512,845, subject to fractional adjustment. Any resulting fractional shares will be rounded up to the nearest whole share, and the new CUSIP number will be 31573L204.
3. Compliance and Equity Impact
The reverse split is intended to meet Nasdaq’s minimum bid price listing requirement and will proportionately adjust the number and exercise price of shares available under the company’s equity incentive plans, as well as outstanding stock options, warrants, and awards. All stockholders will maintain their percentage ownership aside from adjustments related to fractional shares.